{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:46:57Z","timestamp":1791704817986,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2021CXA005"],"award-info":[{"award-number":["2021CXA005"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017357","name":"Science and Technology Projects of Fujian Province","doi-asserted-by":"publisher","award":["2023Y0053"],"award-info":[{"award-number":["2023Y0053"]}],"id":[{"id":"10.13039\/100017357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tranon.2026.103040","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:57:39Z","timestamp":1790110659000},"page":"103040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Genetic evaluation of encorafenib-associated kinases RAF1 and MAPK8 in pancreatic cancer: Exploratory mediation by circulating immune traits"],"prefix":"10.1016","volume":"73","author":[{"given":"Fen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronggui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6737-7201","authenticated-orcid":false,"given":"Zongqi","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.103040_bib0001","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/j.gastro.2020.10.007","article-title":"Worldwide burden of, risk factors for, and trends in pancreatic cancer","volume":"160","author":"Huang","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tranon.2026.103040_bib0002","first-page":"23","article-title":"Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer","author":"Cao","year":"2021","journal-title":"Expert. Rev. Mol. Med."},{"key":"10.1016\/j.tranon.2026.103040_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2022.12.013","article-title":"Liposome-based diagnostic and therapeutic applications for pancreatic cancer","volume":"157","author":"Raza","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.tranon.2026.103040_bib0004","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tranon.2026.103040_bib0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tranon.2026.103040_bib0006","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tranon.2026.103040_bib0007","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.3390\/cancers13164235","article-title":"Challenges and future perspectives of immunotherapy in pancreatic cancer","volume":"13","author":"Wandmacher","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2026.103040_bib0008","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13073-020-00776-9","article-title":"Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions","volume":"12","author":"Lin","year":"2020","journal-title":"Genome Med."},{"key":"10.1016\/j.tranon.2026.103040_bib0009","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ccell.2021.06.017","article-title":"Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity","volume":"39","author":"Hutton","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2026.103040_bib0010","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1084\/jem.20180749","article-title":"Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma","volume":"216","author":"Liu","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tranon.2026.103040_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113992","article-title":"Metabolic reprogramming of immune cells in pancreatic cancer progression","volume":"157","author":"Xiang","year":"2023","journal-title":"Biomed. PharmacOther"},{"key":"10.1016\/j.tranon.2026.103040_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106398","article-title":"A renewed concept on the MAPK signaling pathway in cancers: polyphenols as a choice of therapeutics","volume":"184","author":"Anjum","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tranon.2026.103040_bib0013","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/bs.acr.2023.02.003","article-title":"Interplay between MAP kinases and tumor microenvironment: opportunity for immunotherapy in pancreatic cancer","volume":"159","author":"Kumar","year":"2023","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.tranon.2026.103040_bib0014","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.103040_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103875","article-title":"Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors","volume":"100","author":"Liu","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tranon.2026.103040_bib0016","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-018-0793-1","article-title":"EGFR-TKIs resistance via EGFR-independent signaling pathways","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2026.103040_bib0017","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","article-title":"Encorafenib and binimetinib: first global approvals","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.tranon.2026.103040_bib0018","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/1541-7786.MCR-22-0626","article-title":"BRAF-driven pancreatic cancer: prevalence, molecular features, and therapeutic opportunities","volume":"21","author":"Ciner","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.tranon.2026.103040_bib0019","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s10194-023-01612-2","article-title":"Exploring the bidirectional relationship between pain and mental disorders: a comprehensive Mendelian randomization study","volume":"24","author":"Yao","year":"2023","journal-title":"J. Headache Pain."},{"key":"10.1016\/j.tranon.2026.103040_bib0020","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1055-9965.EPI-17-1177","article-title":"Causal inference in cancer epidemiology: what is the role of Mendelian randomization?","volume":"27","author":"Yarmolinsky","year":"2018","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.tranon.2026.103040_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009238","article-title":"Ten simple rules for conducting a Mendelian randomization study","volume":"17","author":"Gagliano Taliun","year":"2021","journal-title":"PLoS. Comput. Biol."},{"key":"10.1016\/j.tranon.2026.103040_bib0022","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.tranon.2026.103040_bib0023","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.tranon.2026.103040_bib0024","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ccell.2024.08.001","article-title":"The KRAS mutational spectrum and its clinical implications in pancreatic cancer","volume":"42","author":"Perelli","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2026.103040_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103696","article-title":"Efficacy and safety of the combination of encorafenib\/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study","volume":"9","author":"Gallois","year":"2024","journal-title":"ESMo Open."},{"key":"10.1016\/j.tranon.2026.103040_bib0026","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.103040_bib0027","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41388-023-02683-w","article-title":"RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status","volume":"42","author":"Dorard","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2026.103040_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114073","article-title":"COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma","volume":"204","author":"Schadendorf","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2026.103040_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103975","article-title":"Encorafenib, binimetinib and cetuximab in BRAF V600E-mutated advanced pancreatic adenocarcinoma","volume":"9","author":"Zaanan","year":"2024","journal-title":"ESMo Open."},{"key":"10.1016\/j.tranon.2026.103040_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40364-024-00630-9","article-title":"Infiltrating Treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.tranon.2026.103040_bib0031","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103040_bib0032","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.103040_bib0033","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2021.09.011","article-title":"Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF V600-mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial","volume":"158","author":"Zimmer","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2026.103040_bib0034","series-title":"BRAFTOVI (encorafenib) capsules, for oral use: prescribing information","year":"2026"},{"key":"10.1016\/j.tranon.2026.103040_bib0035","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","article-title":"Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial","volume":"30","author":"Kopetz","year":"2024","journal-title":"Nat. Med."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:31:32Z","timestamp":1791703892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326003761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":35,"alternative-id":["S1936523326003761"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103040","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic evaluation of encorafenib-associated kinases RAF1 and MAPK8 in pancreatic cancer: Exploratory mediation by circulating immune traits","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103040"}}